GPX4 and hepatocellular carcinoma: TGF-β1 (transforming growth factor β1) can increase hepatoma cell sensitivity to GPX4 inhibitors by suppressing System xc-, which will benefit GPX4-targeted therapy for hepatoma cells (54).